Fundraisings and IPOs

* On November 19, 2013, Oxford BioMedica, a UK gene-based biopharmaceutical company, has announced that it has signed a £5 million secured loan facility agreement with its largest shareholder, the Vulpes Life Sciences Fund. The loan facility, which constitutes a related party transaction, is conditional upon shareholder approval pursuant to Listing Rule 11 of the Listing Rules of the UK Listing Authority. If approved by shareholders, Oxford BioMedica may draw down the loan in tranches of £1 million or more, as necessary, at any time from 1 January 2014 up until 10 business days before the maturity of the loan on 31 December 2014.  Borrowings under the loan facility will be used for general working capital purposes.  The loan facility is secured against certain intellectual property owned by the Company.

RetinoStat® data are expected in 2014. This programme is the lead programme of the ocular agreement Oxford Biomedica signed with Sanofi in April 2009.

* On June 18, 2014, Oxford BioMedica announced that it has repaid in full the amount drawn down from the £5 million secured loan facility agreement, agreed on 19 November 2013 with its largest shareholder, the Vulpes Life Sciences Fund. On receipt of the £21.6 million (before expenses) raised through the Firm Fundraising and Open Offer, which completed on 17 June 2014, the portion of the Vulpes loan facility which had been drawn down was repaid in full by the Company.